Merck & Co needs to find a way to grow its business once its blockbuster cancer immunotherapy Keytruda hits patent expiry in 2028, and believes a wave of new cardiovascular drugs could help it achieve that goal.
To that end, the company’s executive team, led by research chief Dean Li, showcased its pipeline of cardiovascular therapies on 5 April, projecting eight new drug approvals and expanded labels between 2024 and 2028
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?